NLK Antibody

說明書

中文名稱：

NLK兔多克隆抗體
貨號：

CSB-PA890657ESR1HU
規格：

￥440
圖片：
Immunohistochemistry of paraffin-embedded human breast cancer using CSB-PA890657ESR1HU at dilution of 1:100

Immunohistochemistry of paraffin-embedded human testis tissue using CSB-PA890657ESR1HU at dilution of 1:100
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) NLK Polyclonal antibody
Uniprot No.：

Q9UBE8
基因名：

NLK
別名：

DKFZp761G1211 antibody; FLJ21033 antibody; LAK1 antibody; Nemo like kinase antibody; Nemo-like kinase antibody; Nlk antibody; NLK_HUMAN antibody; Protein LAK1 antibody; Serine/threonine protein kinase NLK antibody; Serine/threonine-protein kinase NLK antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Serine/threonine-protein kinase NLK protein (278-527AA)
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

Antigen Affinity Purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
產品提供形式：

Liquid
應用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:20-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Serine/threonine-protein kinase that regulates a number of transcription factors with key roles in cell fate determination. Positive effector of the non-canonical Wnt signaling pathway, acting downstream of WNT5A, MAP3K7/TAK1 and HIPK2. Negative regulator of the canonical Wnt/beta-catenin signaling pathway. Binds to and phosphorylates TCF7L2/TCF4 and LEF1, promoting the dissociation of the TCF7L2/LEF1/beta-catenin complex from DNA, as well as the ubiquitination and subsequent proteolysis of LEF1. Together these effects inhibit the transcriptional activation of canonical Wnt/beta-catenin target genes. Negative regulator of the Notch signaling pathway. Binds to and phosphorylates NOTCH1, thereby preventing the formation of a transcriptionally active ternary complex of NOTCH1, RBPJ/RBPSUH and MAML1. Negative regulator of the MYB family of transcription factors. Phosphorylation of MYB leads to its subsequent proteolysis while phosphorylation of MYBL1 and MYBL2 inhibits their interaction with the coactivator CREBBP. Other transcription factors may also be inhibited by direct phosphorylation of CREBBP itself. Acts downstream of IL6 and MAP3K7/TAK1 to phosphorylate STAT3, which is in turn required for activation of NLK by MAP3K7/TAK1. Upon IL1B stimulus, cooperates with ATF5 to activate the transactivation activity of C/EBP subfamily members. Phosphorylates ATF5 but also stabilizes ATF5 protein levels in a kinase-independent manner.
基因功能參考文獻：
1. overexpression of miR-221 decreased LEF1 phosphorylation but increased the expression of MYCN via targeting of NLK and further regulated cell cycle, particularly in S-phase. This study provides a novel insight for miR-221 in the control of neuroblastoma cell proliferation and tumorigenesis, suggesting potentials of miR-221 as a prognosis marker and therapeutic target for patients with MYCN overexpressing neuroblastoma. PMID: 28003306
2. NLK is a novel signaling molecule for proper lung development through the interconnection between epithelial and endothelial cells during lung morphogenesis PMID: 27035511
3. Our results suggest that NLK inhibits transcriptional activation of Nurr1 gene by impeding CBP's role as a co-activator of NF-kappaB and CREB in prostate cancer. PMID: 27036119
4. The expression of NLK was negatively correlated with TCF4 expression in lung cancers PMID: 26823848
5. NLK overexpression is an independent prognostic factor in colorectal cancer and knockdown of NLK expression inhibits colorectal cancer progression and metastasis. PMID: 26269673
6. Further experiments demonstrated that the overexpression of miR3623p resulted in decrease expression levels of nemo-like kinase PMID: 26647877
7. NLK was involved in miR-92b-induced cell proliferation, and its protein level was obviously downregulated in the miR-92b-overexpressing xenograft tumors. PMID: 26503628
8. Data show that metformin inhibits nemo like kinase (NLK) expression and might be a potential treatment strategy for non-small cell lung cancer (NSCLC). PMID: 26503334
9. Down-regulation of NLK inhibited tumorigenesis and up-regulated the expression of cell cycle proteins in laryngeal cancer cells. PMID: 26252054
10. In this review, we will make a summary on the comprehensive roles of NLK in the regulation of various cancers PMID: 26427665
11. NLK was an identified miR-199a-3p target gene and functioned as a tumor suppressor gene in colorectal cancer. PMID: 24972723
12. NLK overexpression is associated with poor overall survival in patients with hepatocellular carcinoma(HCC), it might be an independent poor prognostic marker for HCC. PMID: 26022162
13. NLK phosphorylates Raptor on S863 to disrupt its interaction with the Rag GTPase, which is important for mTORC1 lysosomal recruitment. PMID: 26588989
14. our work first demonstrated that miR-197 can confer drug resistance to Taxol, by regulating tumor suppressor, NLK expression in ovarian cancer cells. PMID: 25833695
15. Data indicate that heat-shock protein 27 HSP27) binds to Nemo-like kinase (NLK) in the nucleus. PMID: 24816797
16. NLK is an important p53 regulator that responds to DNA damage. NLK interacts with p53 and stabilizes p53 by blocking MDM2-mediated p53 ubiquitination and degradation. PMID: 24926618
17. High nemo-like kinase expression is associated with drug resistance in laryngeal cancer. PMID: 24460265
18. NLK is a negative regulator in cell proliferation of non-small-cell lung cancer by modulating the activity of Wnt/beta-catenin signaling. PMID: 23904219
19. NLK functions as a pivotal negative regulator of NF-kappaB via disrupting the interaction of TAK1 with IKKbeta. PMID: 24721172
20. The results suggest that NLK silencing by lentivirus-mediated RNA interference would be a potential therapeutic method to control oral squamous carcinoma growth. PMID: 23983589
21. NLK suppressed proliferation, induced apoptosis and mediated c-Myb degradation in MCF-7 cells. PMID: 23935942
22. Data indicate that overexpression of nemo-like kinase (NLK) is closely related to progression of gallbladder cancer (GBC), and NLK could be used as a potential prognostic marker for GBC patients. PMID: 23857283
23. Reduced expression of NLK is associated with glioma. PMID: 23416699
24. Our results suggested that NLK is a key regulator involved in proliferation and migration of GBC, and it could be used as a potential therapeutic target for gallbladder carcinoma cells. PMID: 22733362
25. Single nucleotide polymorphisms in NLK is associated with ovarian cancer. PMID: 22253297
26. expression suppressed in the development of ovarian cancer PMID: 22027747
27. NLK induces apoptosis in glioma cells via activation of caspases; NLK may be a useful independent prognostic indicator for glioma. PMID: 21177110
28. ZIPK may serve as a transcriptional regulator of canonical Wnt/beta-catenin signaling through interaction with NLK/TCF4. PMID: 21454679
29. dimerization is an initial key event required for the functional activation of NLK PMID: 21118996
30. NLK is aberrantly regulated in hepatocellular carcinoma and this process appears to involve the induction of CDK2 and cyclin D1 PMID: 20512928
31. findings provide the first evidence that TAK1-NLK pathway is a novel regulator of FOXO1 PMID: 20061393
32. NLK negatively regulates Notch-dependent transcriptional activation by phosphorylating Notch1ICD. Phosphorylated Notch1ICD is impaired in its ability to form a transcriptionally active ternary complex. PMID: 20118921
33. threonine 9 (Thr9) and Serine 138 (Ser138) within the N-terminal Mad homology1 (MH1) domain of Smad4 could be phosphorylated by NLK PMID: 19690946
34. The induction of wild-type NLK in DLD-1 human colon cancer cells caused suppression of cell growth whereas the kinase-negative mutant did not. PMID: 12901858
35. Nemo-like kinase is activated by Wnt PMID: 14960582
36. STAT3 enhances the efficiency of its own Ser-727 phosphorylation by acting as a scaffold for the TAK1-NLK kinases PMID: 15764709
37. These results strongly suggest that unlike cytokine signaling, Tax-induced NFkappaB activation does not involve K63 polyubiquitination-mediated MAP3K activation. PMID: 17418100
38. Fbxw7, the F-box protein of an SCF complex, targets c-Myb for degradation in a Wnt-1- and NLK-dependent manner. PMID: 18765672
39. NLK expression is altered during prostate cancer progression and it is involved in regulation of AR signaling in these cells PMID: 19514049
顯示更多

收起更多
亞細胞定位：

Nucleus. Cytoplasm.
蛋白家族：

Protein kinase superfamily, CMGC Ser/Thr protein kinase family, MAP kinase subfamily
數據庫鏈接：

HGNC: 29858

OMIM: 609476

KEGG: hsa:51701

STRING: 9606.ENSP00000384625

UniGene: Hs.208759

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human